Myeloproliferative Neoplasms Pipeline Analysis Report 2026

Myeloproliferative neoplasms (MPNs) are rare clonal hematologic malignancies characterized by the excessive production of mature blood cells in the bone marrow due to mutations in hematopoietic stem cells. According to Cancer Therapy Advisor, primary myelofibrosis, one of the major MPN subtypes, has an annual incidence of around 0.3 cases per 100,000 individuals in the United States, with most diagnoses occurring at a median age of 65-67 years. Major therapeutic approaches include JAK inhibitors, interferon therapies, targeted agents, and hematopoietic stem cell transplantation. According to the myeloproliferative neoplasms pipeline analysis, increasing research on molecular drivers, expanding clinical trials, and advancements in targeted therapies are expected to strengthen the development of novel treatments and support pipeline growth in the coming years.

Report Coverage

The Myeloproliferative Neoplasms Pipeline Analysis Report gives comprehensive insights into myeloproliferative neoplasms therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for myeloproliferative neoplasms. The myeloproliferative neoplasms report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The myeloproliferative neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with myeloproliferative neoplasms treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to myeloproliferative neoplasms.

Myeloproliferative Neoplasms Pipeline Outlook

Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers characterized by the abnormal overproduction of blood cells in the bone marrow. They occur due to mutations in genes regulating hematopoietic stem cells, such as Janus kinase 2, leading to uncontrolled cell proliferation. This process disrupts normal blood formation and may progress to bone marrow fibrosis or leukemia.

Myeloproliferative neoplasms treatment focuses on controlling abnormal blood cell production, relieving symptoms, and preventing complications using Janus kinase inhibitors, cytoreductive drugs, targeted therapies, blood transfusions, and hematopoietic stem cell transplantation. Momelotinib gained regulatory momentum in September 2023 when the United States Food and Drug Administration approved the oral Janus kinase 1 and Janus kinase 2 inhibitor for myelofibrosis patients with anemia. Developed by GlaxoSmithKline, the therapy demonstrated improvements in spleen size, symptom burden, and transfusion independence in Phase III trials.

Myeloproliferative Neoplasms Epidemiology

The pipeline is gaining attention due to measurable disease incidence and ongoing clinical research. According to Cancer Therapy Advisor, the annual incidence of primary myelofibrosis in the United States is about 0.3 cases per 100,000 individuals, with a median patient age of 65-67 years. Additionally, as per Nouf Abutheraa et al., 2023, myeloproliferative neoplasms affect nearly 8 individuals per 100,000 population in the United Kingdom. The growing epidemiological burden and improved diagnosis are supporting the continuous research and development of targeted therapies in the pipeline.

Myeloproliferative Neoplasms - Pipeline Therapeutic Assessment

This section of the report covers the analysis of myeloproliferative neoplasms drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The myeloproliferative neoplasms pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Recombinant Proteins
• Peptides
• Vaccines

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Myeloproliferative Neoplasms Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 54%, covers a major share of the total myeloproliferative neoplasms clinical trials, highlighting advanced development and strong market potential. Phase I contributes 34%, reflecting robust early-stage innovation, while phase III accounts for 10%, demonstrating promising late-stage candidates. Together, these developments can drive significant growth and treatment options in the market.

Myeloproliferative Neoplasms Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the myeloproliferative neoplasms pipeline analysis include small molecules, monoclonal antibodies, recombinant proteins, peptides, and vaccines. The myeloproliferative neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for myeloproliferative neoplasms. Targeted immune cell therapies are emerging in the myeloproliferative neoplasms drug pipeline to address unmet needs in myelofibrosis. For instance, CK0804, an allogenic Treg cell therapy, modulates the CXCR4/CXCL12 axis and delivers IL-10 to suppress inflammation. It demonstrates disease-modifying effects, reduces pathogenic monocytes, and complements JAK inhibition, offering an off-the-shelf, non-myelosuppressive treatment option for patients.

Myeloproliferative Neoplasms Clinical Trials - Key Players

The report for the myeloproliferative neoplasms pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed myeloproliferative neoplasms therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in myeloproliferative neoplasms clinical trials:

• AbbVie
• Incyte Corporation
• Eli Lilly and Company
• Janssen Research & Development, LLC
• BeiGene
• Sumitomo Pharma America, Inc.
• Hangzhou GluBio Pharmaceutical Co., Ltd.
• GlaxoSmithKline
• Bristol-Myers Squibb
• Ajax Therapeutics, Inc.
• Telios Pharma, Inc.

Myeloproliferative Neoplasms - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs myeloproliferative neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of myeloproliferative neoplasms drug candidates.

Drug: IMGN632

Pivekimab Sunirine (IMGN632) is being investigated in an ongoing Phase 1/2 open-label, multi-center clinical study sponsored by AbbVie for patients with untreated or relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and other CD123-positive hematologic malignancies, including myeloproliferative neoplasms. The study is evaluating the maximum tolerated dose, safety, tolerability, pharmacokinetics, immunogenicity, and anti-leukemia activity of the drug. Pivekimab Sunirine is a CD123-targeted antibody-drug conjugate administered intravenously on Day 1 of a 21-day cycle, delivering a cytotoxic payload directly to malignant cells to enhance targeted cell killing. The trial started in January 2018 and is expected to be completed in December 2026.

Drug: INCA035784

INCA035784 is a novel T-cell redirecting antibody being developed by Incyte Corporation for the treatment of myeloproliferative neoplasms. The Phase 1, open-label, multicenter study is evaluating the safety, tolerability, and preliminary clinical activity of the drug in approximately 120 participants. INCA035784 is designed to recognize mutant calreticulin (mutCALR) on malignant cells and simultaneously activate T cells, triggering targeted immune-mediated destruction of mutCALR-positive cancer cells. The therapy is being administered as a systemic antibody treatment and is demonstrating dose-dependent T-cell activation with controlled cytokine release. The study started in October 2025 and is expected to be completed by December 2029.

Drug: JNJ-88549968

JNJ-88549968 is being evaluated in a Phase 1 clinical study sponsored by Janssen Research & Development, LLC, for the treatment of calreticulin (CALR)-mutated myeloproliferative neoplasms. The objective of this phase is to assess safety, pharmacokinetics, and pharmacodynamics while determining the recommended Phase 2 dose and optimal dosing schedule. JNJ-88549968 is a T-cell-redirecting bispecific antibody designed to selectively target CALR-mutated MPN clones and stimulate T-cell-mediated immune responses against malignant cells. The therapy is being administered as monotherapy for essential thrombocythemia or myelofibrosis and in combination with ruxolitinib or momelotinib in myelofibrosis patients. The study is expected to be completed in December 2027.

Key Questions Answered in the Myeloproliferative Neoplasms Pipeline Insight Report

• Which companies/institutions are leading the myeloproliferative neoplasms drug development?
• Which company is leading the myeloproliferative neoplasms pipeline development activities?
• What is the current myeloproliferative neoplasms commercial assessment?
• What are the opportunities and challenges present in the myeloproliferative neoplasms pipeline landscape?
• What is the efficacy and safety profile of myeloproliferative neoplasms pipeline drugs?
• Which company is conducting major trials for myeloproliferative neoplasms drugs?
• Which companies/institutions are involved in myeloproliferative neoplasms collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in myeloproliferative neoplasms?

Reasons To Buy This Report

The Myeloproliferative Neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for myeloproliferative neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into myeloproliferative neoplasms collaborations, regulatory environments, and potential growth opportunities.